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Background
TGR5 (M-BAR, GPBAR or GPR131) is a plasma mem-
brane-bound, G protein-coupled receptor for bile acids,
expressed in many human cells. The aim of this study
was to describe that targeting TGR5 could provide an
exciting new pharmacological approach to improve dif-
ferent aspects of the metabolic syndrome in humans.
Methods
The data on pharmacological targeting of TGR5 have
been provided from more than eighty review and original
scientific articles, published from 2007 to 2012. The
research was performed using the following key words:
bile acids, TGR5, metabolism, diabetes, obesity.
Results
A dietary supplementation of bile acids (BAs) significantly
reduced body weight in mice fed with a fat-rich diet. It
was the consequence of the induction of deiodinase 2 (D2)
through a TGR5/cAMP-mediated pathway. D2 is able to
induce the conversion of inactive thyroxine (T4) into the
active 3,5,3′-tri-iodothyronine (T3), which enhances the
energy expenditure in brown adipose tissue (BAT) and
skeletal muscle myoblasts. TGR5 induces glucagon-like
peptide-1 (GLP-1) secretion in cultured mouse enteroen-
docrine STC-1 cells. This property contributes to benefi-
cial effects of TGR5 on glucose metabolism and improves
insulin sensitivity. TGR5 activation in mice decreased
serum and liver triglyceride levels. The anti-inflammatory
action of TGR5 in mouse macrophages attenuated the
development of atherosclerotic lesions and could contri-
bute to protective effects of TGR5 on liver steatosis.
Conclusions
TGR5 may be targeted by natural compounds as well as by
synthetic agonists. Despite the fact that targeting TGR5 in
animals brings great promise for metabolic syndrome
treatment, multiple studies described the side effects of
targeting TGR5 and further clinical studies are needed to
evaluate and identify safe and efficient TGR5 agonists.
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